New hope for IBS sufferers: gelsectan trial launches in vietnam
NCT ID NCT07000383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether Gelsectan, a supplement that coats the gut, can reduce diarrhea, belly pain, and bloating in people with diarrhea-predominant irritable bowel syndrome (IBS-D). About 90 adults in Vietnam will be randomly assigned to take Gelsectan alone, Gelsectan plus a standard antispasmodic drug, or the drug alone for two months. Researchers will track symptom changes and side effects to see if Gelsectan offers better relief than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jul 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of IBS-D based on the Rome IV criteria,8 including: * Recurrent abdominal pain occurring at least one day per week in the last three months, associated with at least two of the following: related to defecation, associated with a change in stool frequency, or associated with a change in stool form. These criteria must have been present during the last three months, with symptom onset at least six months prior to diagnosis; * More than 25% of bowel movements with stool types 6 or 7 and less than 25% with stool types 1 or 2 according to the Bristol Stool Form Scale. * Signed informed consent for study participation Exclusion Criteria: * Pregnant or breastfeeding women * Known allergy to any component of the study medication * Diagnosed with diabetes mellitus * Patients with severe comorbidities or psychiatric disorders that impair their ability to complete questionnaires or attend follow-up visits
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diarrhea-predominant irritable bowel syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Medical Center Ho Chi Minh City
RECRUITINGHo Chi Minh City, District 5, 700000, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.